In Vivo Efficacy and Pharmacokinetics of the 2-Aminomethylphenol Antimalarial JPC-3210 in the Aotus Monkey-Human Malaria Model | Zendy

Fiona J. McCallum | Zendy; Geoffrey W. Birrell | Zendy; Marina Chavchich | Zendy; Ivor Harris | Zendy; Nicanor Obaldía | Zendy; Karin van Breda | Zendy; Gavin D. Heffernan | Zendy; David P. Jacobus | Zendy; G. Dennis Shanks | Zendy; Michael D. Edstein | Zendy

Open Access

In Vivo Efficacy and Pharmacokinetics of the 2-Aminomethylphenol Antimalarial JPC-3210 in the Aotus Monkey-Human Malaria Model

Author(s) -

Fiona J. McCallum,

Geoffrey W. Birrell,

Marina Chavchich,

Ivor Harris,

Nicanor Obaldía,

Karin van Breda,

Gavin D. Heffernan,

David P. Jacobus,

G. Dennis Shanks,

Michael D. Edstein

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01538-19

Subject(s) - plasmodium falciparum , plasmodium vivax , malaria , in vivo , pharmacokinetics , pharmacology , biology , potency , virology , in vitro , immunology , biochemistry , microbiology and biotechnology

Nonimmune Aotus monkeys infected with Plasmodium falciparum and Plasmodium vivax were cured of their infections when treated with a single oral dose of 5 mg/kg and 10 mg/kg of the 2-aminomethylphenol, JPC-3210, respectively. Corresponding mean blood elimination half-lives of JPC-3210 were lengthy at 19.1 days and 20.5 days, respectively. This in vivo potency and lengthy half-life supports the further development of JPC-3210 as a promising, long-acting blood schizontocidal antimalarial for malaria treatment and prevention.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research